A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)

Launched by MERCK SHARP & DOHME LLC · Mar 18, 2025

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Inclusion criteria include, but are not limited to:
• • Is a healthy, adult, male or female of non-childbearing potential only, 18-55 years of age, inclusive
• • Is a continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior
• Exclusion Criteria:
• Exclusion criteria include, but are not limited to:
• * Has a history or presence of:
• • Seizures (except for febrile seizure), or is at an increased risk for seizures
• • Family history of severe dermatologic reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome
• • Clinically meaningful hematologic diseases, bone marrow disorders, or hematologic adverse reactions to other medications
• • Depression, unusual changes in mood or behavior or suicidal thoughts or behavior
• • Hypersensitivity reaction to anticonvulsant therapy (including phenytoin, primidone, and phenobarbital)
• • Clinically significant eye disease
• • Shown to carry or be positive for HLA-A\*11:01, HLA-A\*31:01, HLA-B\*15:02, HLA-B\*15:08, HLA-B\*15:11, HLA-B\*15:21, HLA-B\*15:30, or HLA-B\*15:31 alleles.

Trial Officials